All Articles

Kyntra Bio's Q2 profit was driven by a one-time accounting gain, masking operating losses. Now, the firm bets its future on two critical Q4 data readouts.

Soluna Holdings reports a 145% revenue surge but a widening net loss, revealing a bold strategy to trade short-term profits for a vast green AI infrastructure.

With a cash runway to 2029 and a novel cancer drug nearing key data, NuCana signals quiet confidence in a high-stakes race to treat resistant melanoma.

With a $115M financing and an expanded pipeline, Assembly Biosciences is betting on novel therapies for liver and viral diseases. But can it navigate a crowded field?

After years of losses, Smith Micro's Q2 results show a dramatic improvement in profitability, driven by deep cost cuts and a strategic shift beyond carriers.

Freeman Gold's new feasibility study reveals a $1B+ valuation for its Idaho project, but can it navigate the path from blueprint to bullion in a volatile market?

Beyond the hype of a multi-billion dollar investment, Lam Research is re-engineering the very speed of innovation to meet AI's relentless demands.

Brandon Hall Group's 2026 HCM Excellence Awards spotlight the firms winning the war for talent. Here's why investors should pay attention to these benchmarks.

The InsurTech firm posted a Q2 loss and falling revenue, but its forward-looking metrics tell a different story. A deep dive into a high-stakes bet on AI.

A San Diego biotech is advancing a device to clean the blood of disease-fueling particles. With early promise in cancer and a new path in Long COVID, can it navigate the financial realities of innovation?

With over $1B in cash, Nektar is pushing its novel drug, rezpegaldesleukin, into final trials. It's a high-stakes bet on a new era for autoimmune care.

A biotech startup's nomination for a top award validates its unique platform, which uses a patient's own cells to fight cancer and prepare for future pandemics.

Inhibrx Biosciences lands a massive new loan to fuel its promising cancer drug trials, but rising costs and a wider net loss paint a high-stakes picture.

Matic's new intuitive robot interface arrives just as FCC rules reshape the market, making American assembly and data privacy the new keys to the kingdom.

For two decades, NVIDIA's CUDA software has been an insurmountable wall for chip rivals. Now, a startup's AI agent claims to build that wall in days.

As Toronto prepares a final salute to the Snowbirds, their grounding reveals a strategic military shift and a major air show's plan for reinvention.

St. Albert Transit's order for 13 diesel buses isn't a retreat from green goals, but a strategic move to bridge the gap between today's needs and tomorrow's electric future.

From car alternators to EV batteries, TERREPOWER's rebrand is more than a tagline. It's a high-stakes test for the future of industrial sustainability.

With mounting losses and a CEO's unyielding optimism, activist investors issue an ultimatum: take proteomics firm Seer private or face the consequences.

When a company replaced a teen's stolen medical wish, it was more than charity. It was a masterclass in brand strategy in the high-stakes e-mobility market.